Agree. I'm starting to come around to yesterday's news as the more exciting option, despite the dilution which was a shock. Mateo make good point - what would an actual partnership at this stage look like, maybe favourable to us but also good chance more favourable to the pharma, we will never know.
This big CR also gains us much needed exposure with the AFR articles and the like and validates the idea that this drug really has potential, outside of us believers. We need exposure to all kinds of investors to drive up SP. This option also allows us to completely own the asset if AA does come through, obviously would change everything. I always mention them, but if AA does come through we would look similar to Reata Pharma - similar drug both with wider potential, similar-ish disease, similar position if we get AA , i.e. pre-launch. So I'm telling myself be patient until the further analysis and possible FDA talks. Cheers.
ATH Price at posting:
1.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)